Interagency Patent Coordination and Improvement Act of 2025

4/15/2025, 4:23 AM
Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.
Bill 119 s 1097, also known as the "Interagency Task Force on Patents and FDA Collaboration Act," aims to amend title 35 of the United States Code to create a partnership between the United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA). The main goal of this bill is to facilitate the sharing of information and technical assistance between these two agencies in relation to patents.

The bill proposes the establishment of an interagency task force that will be responsible for coordinating efforts between the USPTO and FDA. This task force will work towards improving communication and collaboration between the two agencies, with the ultimate aim of streamlining the patent process for products regulated by the FDA.

Additionally, the bill outlines the specific responsibilities of the task force, which include sharing information on patent applications related to FDA-regulated products, providing technical assistance to patent examiners and FDA reviewers, and identifying areas where the patent and regulatory processes can be harmonized. Overall, the Interagency Task Force on Patents and FDA Collaboration Act seeks to enhance cooperation between the USPTO and FDA in order to promote innovation, protect intellectual property rights, and ensure the safety and efficacy of FDA-regulated products.
Congress
119

Number
S - 1097

Introduced on
2025-03-24

# Amendments
0

Sponsors
+5

Cosponsors
+5

Variations and Revisions

3/24/2025

Status of Legislation

Bill Introduced
Introduced to House
House to Vote
Introduced to Senate
Senate to Vote

Purpose and Summary

Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.
Bill 119 s 1097, also known as the "Interagency Task Force on Patents and FDA Collaboration Act," aims to amend title 35 of the United States Code to create a partnership between the United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA). The main goal of this bill is to facilitate the sharing of information and technical assistance between these two agencies in relation to patents.

The bill proposes the establishment of an interagency task force that will be responsible for coordinating efforts between the USPTO and FDA. This task force will work towards improving communication and collaboration between the two agencies, with the ultimate aim of streamlining the patent process for products regulated by the FDA.

Additionally, the bill outlines the specific responsibilities of the task force, which include sharing information on patent applications related to FDA-regulated products, providing technical assistance to patent examiners and FDA reviewers, and identifying areas where the patent and regulatory processes can be harmonized. Overall, the Interagency Task Force on Patents and FDA Collaboration Act seeks to enhance cooperation between the USPTO and FDA in order to promote innovation, protect intellectual property rights, and ensure the safety and efficacy of FDA-regulated products.
Alternative Names
Official Title as IntroducedA bill to amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.

Policy Areas
Commerce

Potential Impact
Administrative remedies•
Department of Commerce•
Drug safety, medical device, and laboratory regulation•
Food and Drug Administration (FDA)•
Intellectual property•
Intergovernmental relations

Comments

Recent Activity

Latest Action4/10/2025
Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.